Who
John E. Bishop
Officer
Company insider
Files Form 4 as: Officer, Ardelyx; Chief Technology Officer, Lyra Therapeutics; SVP, Chief Technology Officer, Forma Therapeutics Holdings; Senior VP, Pharmaceutical Scie, Momenta Pharmaceuticals.
In numbers
- Trades disclosed
- 294
- Buys
- 0
- Sells
- 147
- Bought
- $0
- Sold
- $7.2M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 17 Feb 2006
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $67K17,281 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,5232,469 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $67K17,281 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $9,5302,469 at $3.86 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $14K2,306 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $14K2,306 at $6.27 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $16K2,792 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $2,206386 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $61 at $5.70 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $16K2,792 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $2,204386 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $61 at $5.70 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —124,330 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,500 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,500 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —124,330 at $0.00 | filing |
| 30 Jan 2024filed 1 Feb 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 27 Feb 2023filed 28 Feb 2023 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —67,000 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —38,930 | filing |
News
Pomerantz LLP Issues Important Reminder to Investors in Ardelyx, Inc. ...ARDX · pr-inside.com · 25 Oct 2026Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersARDX · manilatimes.net · 23 Oct 2026November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026
0 headlines in the last 90 days name John E. Bishop; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.